LBPH Longboard Pharmaceuticals, Inc. Company Net Income

Official company branding of longboardpharma.com (LBPH)

Longboard Pharmaceuticals (LBPH) profits on the GURU.Markets chart timeline, where -0.08 indicates the value of this parameter, highlight the company's dependence on Bexicaserin trials and regulatory approvals. The deal with Lundbeck eliminated the financial deficit, ensuring a steady pace for final testing. Simultaneously, Longboard Pharmaceuticals (LBPH) is developing a treatment system for rare neurological pathologies, implementing new standards of care for children with epilepsy.

Company Net Income: longboardpharma.com (LBPH) for 07/04/2022 - 12/07/2024

Financial and market metric breakdowns for Longboard Pharmaceuticals, Inc. (LBPH)

- stock value and consensus price forecast:
Market Price Longboard|LBPH - Price Target Chart
- market capitalization data:
Market Value Longboard|LBPH - Total Company Value
- book capitalization indicators:
Net Asset Value per Share Longboard Pharmaceuticals|LBPH - Company Book Value|Capitalization to Book Value Ratio longboardpharma.com|LBPH - Company Total Assets
- debt and liquidity details:
Debt to Capital Ratio Longboard Pharmaceuticals|LBPH - Long-Term Debt to Capital|Short-Term Debt to Equity Longboard Pharmaceuticals Inc|LBPH - Company Debts|Debts to Book Value Longboard|LBPH - Company Long-Term Debts|Company Short-Term Debts Longboard Pharmaceuticals|Intermediate Coverage Ratio longboardpharma.com
- company profitability and valuation multiples indicators:
LBPH - Net Profit
Basic company analysis:LBPH Longboard
Original product of Longboard Pharmaceuticals Inc

The rapid development of Longboard Pharmaceuticals (LBPH) in the rare neurological disease therapy segment requires precise monitoring of R&D cost efficiency. An analysis of the company's profit levels allows for the verification of actual operational profitability, separating real financial success from liquidity risks, which is critical for assessing the stability of investor capital amid fierce market competition.

Direct competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|Company Net Income RGC|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACAD - Company Net Income|Company Net Income Xenon Pharmaceuticals Inc XENE|VKTX: Company Profit|Supernus Pharmaceuticals - Net Profit|Annual Net Income catalystpharma.com (CPRX)|DNLI: Net Profit|HRMY (Harmony Biosciences Inc) - Company Net Income|Company Net Income Biohaven Pharmaceutical|Company Net Income Amylyx Corp AMLX|Net Profit TRVI|Net Profit praxismedicines.com (PRAX)|Company Net Income Anavex Life Sciences Corp. AVXL|Final Profit CBLL|Prothena Biosciences - Net Profit|ALEC (Alector, Inc.) - Company Profit|ANNX (Annexon, Inc.) - Net Income|Omeros - Final Profit|Company Net Income Neurogene|AC Immune S.A. - Profit After Tax|Net Profit VYGR|NMRA (Neumora Corp) - Final Profit|Net Profit SCLX (Scilex Holding Company)|Net Profit tevogen.com TVGN|ACOG - Company Net Income|Final Profit CGTX (cogrx.com)|Inhibikase (IKT) - Company Net Income|Net Income Cassava Pharma|ASRT (Assertio Holdings) - Net Profit|Net Profit Coya|Net Profit VTGN|Net Income ovidrx.com OVID|Net Profit ABOS (Acumen Pharma)|CervoMed Corporation (CRVO) - Company Net Income|ATHE: Net Income|CLNN - Net Profit|PEPG (pepgen.com) - Net Income|JUNS: Profit After Payment of Taxes|RLMD (Relmada) - Net Profit|Annovis Bio Corporation (ANVS) - Net Financial Result|Net Profit GRCE|Net Income fireflyneuro.com AIFF|Net Profit KLTO (Klotho Neurosciences)|Net Profit NeuroSense Therapeutics Ltd NRSN|RVPH - Company Net Income|MTVA: Company Net Income|NeurAxis, Inc. (NRXS) - Company Net Income|HSDT - Net Financial Result|Company Net Income Passage Bio Inc.|Company Net Income NEUP|Net Profit NERV|Company Net Income ATHA (Athira Pharma Corp)|Company Net Income Addex Therapeutics ADXN|ALZN (Alzamend Neuro Inc.) - Profit After Tax|Cyclerion - Net Profit|Final Profit PTIX (Protagenic Therapeutics)|pasitheaclinics.com (KTTA) - Company Net Income|Company Profit CRGT|ATXI (Avenue Therapeutics) - Net Profit|Company Net Income brainstorm-cell.com BCLI|Net Income CARA (Cara Therapeutics)|Net Profit Chromocell Therapeutics Corp (CHRO)|Company Net Income Eliem Therapeutics Inc. ELYM|Final Profit ITCI|MRNS - Company Net Income|Company Net Income nkgenbiotech.com|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|SAGE (Sage Therapeutics Inc.) - Company Net Income|Company Net Income Neurotrope|Company Net Income Trevena Inc TRVN|Company Net Income Vigil Neuroscience (VIGL)|Anew Medical Inc. - Company Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)